CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 260 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $403,078 | -20.0% | 7,463 | +0.9% | 0.09% | -24.0% |
| Q1 2024 | $503,919 | +14.0% | 7,393 | +4.7% | 0.12% | +7.1% |
| Q4 2023 | $442,019 | +38.9% | 7,061 | +0.7% | 0.11% | +22.8% |
| Q3 2023 | $318,233 | -19.2% | 7,011 | 0.0% | 0.09% | -17.1% |
| Q2 2023 | $393,671 | +22.1% | 7,011 | -1.7% | 0.11% | +16.8% |
| Q1 2023 | $322,492 | +1079.3% | 7,130 | -7.8% | 0.10% | +41.8% |
| Q4 2022 | $27,347 | -99.9% | 7,730 | 0.0% | 0.07% | -35.6% |
| Q3 2022 | $43,593,000 | -1.1% | 7,730 | 0.0% | 0.10% | +4.0% |
| Q2 2022 | $44,088,000 | -0.1% | 7,730 | -2.5% | 0.10% | +3.1% |
| Q1 2022 | $44,115,000 | +0.4% | 7,930 | +3.5% | 0.10% | -3.0% |
| Q4 2021 | $43,953,000 | +0.4% | 7,660 | +104.3% | 0.10% | -1.0% |
| Q3 2021 | $43,779,000 | +11.4% | 3,750 | +28.9% | 0.10% | +11.0% |
| Q2 2021 | $39,285,000 | +32.9% | 2,910 | +3.6% | 0.09% | +16.7% |
| Q1 2021 | $29,557,000 | -3.5% | 2,810 | +836.7% | 0.08% | -7.1% |
| Q4 2020 | $30,637,000 | +22.1% | 300 | -25.0% | 0.08% | +663.6% |
| Q3 2020 | $25,100,000 | +13.7% | 400 | -34.6% | 0.01% | -15.4% |
| Q2 2020 | $22,069,000 | -13.3% | 612 | -29.0% | 0.01% | -23.5% |
| Q1 2020 | $25,457,000 | +636325.0% | 862 | +762.0% | 0.02% | – |
| Q2 2019 | $4,000 | -99.9% | 100 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $2,857,000 | -32.5% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $4,234,000 | -29.5% | 100 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $6,005,000 | +130.3% | 100 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $2,607,000 | +32.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,970,000 | +22.9% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,603,000 | -19.2% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,985,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |